Lack of Usefulness of Literature‐Based Helicobacter pylori Resistance Data for Predicting First‐Line Empirical Treatment Effectiveness in the European Registry on H. pylori Management (Hp‐ EuReg )
Helicobacter · 2026-11 · 31 (6)
DOI: 10.1111/hel.70169 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Helicobacter, online erschienen am 05.11.2026. Verfasst von Ismail Kirrout und 50 weiteren Autor:innen. Beteiligte Einrichtung: Methodology Unit, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Rheumatology Service, Hospital Universitario de La Princesa, Madrid, …. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Drug Resistance, Bacterial, Helicobacter Infections, Helicobacter pylori. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Helicobacter and Microbiota Study Group (EHMSG), Spanish Association of Gastroenterology (AEG), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD).
Abstract (Originalsprache)
Background
Helicobacter pylori ( H. pylori ) infection causes gastritis, peptic ulcer disease, and gastric cancer. Without an effective vaccine, eradication therapy remains crucial. However, increasing antibiotic resistance compromises treatment effectiveness.
Objective
To evaluate whether literature‐based resistance data could predict first‐line empirical treatment effectiveness.
Methods
Resistance rates for clarithromycin, metronidazole, and levofloxacin were extracted from bibliographic reviews and estimated for three timeframes: the treatment year, the preceding year, and the last five years average. These rates (2008–2024) were matched with outcomes from the European Registry on H. pylori Management (Hp‐EuReg, WorldHpReg partner), a prospective real‐world study involving 40 countries. Analyses included Spearman's correlations, multivariate logistic regressions adjusted for demographic, clinical, and therapeutic‐related variables, bootstrap resampling stratified by eradication success, and Random Forest models.
Results
Analysis included 37,659 patients receiving first‐line empirical treatment from 13 countries. Moderate negative correlations were observed between metronidazole and clarithromycin resistances for some regimens. In the regression model, including either contemporaneous or previous‐year resistance rates, clarithromycin resistance showed a negligible positive association, while metronidazole resistance was negatively associated. In regimen‐specific models, previous‐year clarithromycin resistance was positively associated with success in concomitant therapy, whereas higher five‐year mean clarithromycin resistance reduced eradication odds in quadruple clarithromycin–amoxicillin–bismuth therapy. Random Forest models identified compliance, proton‐pump inhibitor dose, regimen duration, and treatment as the strongest predictors of eradication, while resistance variables contributed minimally.
Conclusion
Literature‐based resistance data are not useful for guiding real‐world first‐line H. pylori therapy, highlighting the need for individualized antibiotic susceptibility testing to obtain reliable resistance information. Trial Registration ClinicalTrials.gov identifier: NCT02328131
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Methodology Unit, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Rheumatology Service, Hospital Universitario de La Princesa, Madrid, Spain.
- Centro de Biotecnología y Genómica de Plantas UPM-INIA/CSIC (CBGP), Universidad Politécnica de Madrid, Madrid, Spain.
- Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de…
- Department of Gastroenterology, Hospital Universitario Costa del Sol, RICAPPS-Red de Investigación en Cronicidad, Atención Primaria y Prevención y Promoción de la Salud, Marbella, Spain.
- Department of Gastroenterology, DC Rogaska, Rogaska Slatina, Slovenia.
- A.S. Loginov Moscow Clinical Scientific Center, Moscow, Russia.
ORCID-Profile: Ismail Kirrout, Olga P Nyssen, Ángeles Pérez-Aísa, Bojan Tepes, Samuel J Martínez-Domínguez, Alfredo J Lucendo, Sayar R Abdulkhakov, Maja Denkovski, Javier Tejedor-Tejada, Jose M Huguet, Boris D Starostin, Antonietta G Gravina, Manuel Pabón-Carrasco, Sergey A Alekseenko, Óscar Núñez, Miguel Areia, Jesús Barrio, Antonio Moreno Loro, Blas José Gómez Rodríguez, María Soledad Marcos, Inmaculada Ortiz-Polo, Igor Bakulin, Virginia Flores, Manuel Jiménez-Moreno, Dmitry S Bordin, Antonio Gasbarrini, Wojciech Marlicz, Perminder S Phull, Marino Venerito, Doron Boltin, Lyudmila Boyanova, Pablo Parra, Leticia Moreira, Francis Mégraud, Colm O'Morain, Nuria Montes, Javier P Gisbert
Förderung
- European Helicobacter and Microbiota Study Group (EHMSG)
- Spanish Association of Gastroenterology (AEG)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD)
- European Union programme HORIZON
- UK Research and Innovation
- European Union programme EU4Health
- Asociación Española de Gastroenterología
Zitieren
APA
Kirrout, I., Nyssen, O. P., Pérez-Aísa, Á., Tepes, B., Voynovan, I. N., Martínez-Domínguez, S. J., Lucendo, A. J., Vologzanina, L. G., Pavoni, M., Abdulkhakov, S. R., Denkovski, M., Tejedor-Tejada, J., Ilchishina, T., Bujanda, L., Sarsenbaeva, A. S., Huguet, J. M., Zaytsev, O., Starostin, B. D., Perona, M., …, & Hp‐EuReg investigators (2026). Lack of Usefulness of Literature‐Based Helicobacter pylori Resistance Data for Predicting First‐Line Empirical Treatment Effectiveness in the European Registry on H. pylori Management (Hp‐ EuReg ). Helicobacter, 31(6). https://doi.org/10.1111/hel.70169
Vancouver
Kirrout I, Nyssen OP, Pérez-Aísa Á, Tepes B, Voynovan IN, Martínez-Domínguez SJ, et al. Lack of Usefulness of Literature‐Based Helicobacter pylori Resistance Data for Predicting First‐Line Empirical Treatment Effectiveness in the European Registry on H. pylori Management (Hp‐ EuReg ). Helicobacter. 2026;31(6). doi:10.1111/hel.70169
BibTeX
@article{Kirrout2026,
author = {Kirrout, Ismail and Nyssen, Olga P and Pérez-Aísa, Ángeles and Tepes, Bojan and Voynovan, Irina N and Martínez-Domínguez, Samuel J and Lucendo, Alfredo J and Vologzanina, Ludmila G and Pavoni, Matteo and Abdulkhakov, Sayar R and Denkovski, Maja and Tejedor-Tejada, Javier and Ilchishina, Tatiana and Bujanda, Luis and Sarsenbaeva, Aiman S and Huguet, Jose M and Zaytsev, Oleg and Starostin, Boris D and Perona, Monica and Gravina, Antonietta G and Pabón-Carrasco, Manuel and Alekseenko, Sergey A and Núñez, Óscar and Areia, Miguel and Barrio, Jesús and Loro, Antonio Moreno and Andreev, Dmitry N and Rodríguez, Blas José Gómez and Marcos, María Soledad and Ortiz-Polo, Inmaculada and Tarasova, Galina N and Bakulin, Igor and Alonso, Mónica Sánchez and Arteagoitia, Irene and Flores, Virginia and Jiménez-Moreno, Manuel and Bordin, Dmitry S and Gasbarrini, Antonio and Marcos-Pinto, Ricardo and Marlicz, Wojciech and Phull, Perminder S and Venerito, Marino and Boltin, Doron and Boyanova, Lyudmila and Parra, Pablo and Moreira, Leticia and Mégraud, Francis and O'Morain, Colm and Montes, Nuria and Gisbert, Javier P and Hp‐EuReg investigators, Hp‐EuReg investigators},
title = {Lack of Usefulness of Literature‐Based Helicobacter pylori Resistance Data for Predicting First‐Line Empirical Treatment Effectiveness in the European Registry on H. pylori Management (Hp‐ EuReg )},
journal = {Helicobacter},
year = {2026},
volume = {31},
number = {6},
doi = {10.1111/hel.70169}
}
EUVIMED